# A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities

> **NCT07394374** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cullgen (Shanghai),Inc** · enrollment: 42 (estimated)

## Conditions studied

- Solid Tumors Harboring NTRK Fusion
- NTRK
- NTRK Gene Fusion
- NTRK Fusion Positive

## Interventions

- **DRUG:** CG001419 tablets

## Key facts

- **NCT ID:** NCT07394374
- **Lead sponsor:** Cullgen (Shanghai),Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-20
- **Primary completion:** 2030-08-30
- **Final completion:** 2030-08-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07394374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07394374, "A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07394374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*